Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0N4VB
|
|||
Drug Name |
NLG802
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
Company |
NewLink Genetics Ames, IA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Inhibitor | [1] |
BioCyc | Superpathway of tryptophan utilization | |||
Tryptophan degradation | ||||
L-kynurenine degradation | ||||
Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
NAD de novo biosynthesis | ||||
KEGG Pathway | Tryptophan metabolism | |||
Metabolic pathways | ||||
African trypanosomiasis | ||||
NetPath Pathway | TSLP Signaling Pathway | |||
IL5 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | ||||
Pathwhiz Pathway | Tryptophan Metabolism | |||
Reactome | Tryptophan catabolism | |||
WikiPathways | Tryptophan metabolism | |||
Metabolism of amino acids and derivatives |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.